Xyphos is committed to developing a flexible and controllable CAR-T cell therapy to provide patients with a potential cancer cure. Our ACCEL technology enables the precise control of CAR-T cells based on any tumor-specific antibody, thereby providing a therapeutic platform that:
- Improves CAR-T safety and accesses new target space
- Prevents tumor recurrence by enabling target switching or multiplexing,
- Broadens potential indications through deployment of a convertibleCAR-T therapeutic
Backed by strong issued and pending patents, Xyphos is merging cellular and antibody therapeutics to achieve safety, efficacy and versatility – ultimately bringing promising therapies to cancer patients.